转自：北京日报客户端 "韩中友好交往源远流长，现实利益紧密相连，互为重要近邻和合作伙伴。"韩国新任驻华大使卢载宪日 前在接受本报记者专访时表示，他将致力于强化韩中战略沟通、促进商界互惠合作、提升民众情感共 鸣，推动落实两国元首会谈成果，给两国人民带来更多福祉。 10月30日至11月1日，习近平主席赴韩国庆州出席亚太经合组织第三十二次领导人非正式会议并对韩国 进行国事访问。"这是习近平主席时隔11年再次对韩国进行国事访问，也是李在明总统就任后，两国元 首首次会谈，对引领双边关系发展意义重大，也将对地区和平与繁荣作出更多贡献。"卢载宪表示，两 国领导人一致认为，尽管内外环境不断变化，但韩中两国利益交融、互利共赢的合作属性没有改变，双 方将充分运用既有宝贵经验，共同探寻未来发展方向，推动韩中战略合作伙伴关系行稳致远。 "我很荣幸在现场欢迎习近平主席到访，并见证了两国关系发展的重要历史时刻。"卢载宪回忆道，两国 元首会谈气氛友好坦诚，取得了一系列积极成果。"其间，习近平主席还以温暖的话语对我的履新表示 欢迎，对此我十分感激。"卢载宪说。 卢载宪的父亲卢泰愚在1988年至1993年担任韩国总统期间，积极推行"北方政策" ...

Group 1 - The new South Korean ambassador to China, Lu Zaixian, aims to strengthen strategic communication and promote mutual cooperation between South Korea and China, enhancing the welfare of both nations [1] - The upcoming visit of President Xi Jinping to South Korea marks a significant moment in bilateral relations, being his first state visit in 11 years and the first meeting with the new South Korean president [1] - Both leaders agree that despite changing internal and external environments, the cooperative nature of South Korea-China relations remains unchanged, focusing on mutual benefits and exploring future development directions [1][2] Group 2 - The ambassador emphasizes the importance of deepening cooperation in emerging fields such as artificial intelligence, biopharmaceuticals, green industries, and the silver economy, which are seen as future economic growth drivers [2] - The future of South Korea-China relations is rooted in the friendship between the peoples of both countries, highlighting the significance of youth exchanges and mutual understanding [2] - The ambassador expresses a strong sense of responsibility and mission in his role, aiming to create meaningful outcomes in the development of South Korea-China relations [3]

卢载宪的父亲卢泰愚在1988年至1993年担任韩国总统期间，积极推行"北方政策"，致力于与社会主义国 家改善关系。在他的任内，中韩两国于1992年正式建立外交关系。在卢载宪看来，韩中制度、理念不 同，33年前的建交曾被视为不可能的事，然而两国领导人和人民凭借着非凡的智慧、勇气和远见，求同 存异、同心协力，最终冲破重重阻碍，翻开了两国关系新的一页。自那之后，韩中双边关系发展取得诸 多成就，为各自国家和人民带来巨大福祉。"正如习近平主席所说，韩中'是搬不走的重要近邻，也是分 不开的合作伙伴'。我们要坚守建交初心，继承先辈智慧，增进互信理解，将彼此视为不可或缺的重要 邻居，推动双边关系持续向前发展。"卢载宪说。 近年来，中韩两国产业逐步从互补垂直分工转向水平紧密合作。卢载宪表示，此次元首会谈期间，韩中 双方同意深挖人工智能、生物制药、绿色产业、银发经济等新兴领域合作潜力，具有重要意义。卢载宪 说："这些领域代表着未来经济增长动力源泉，将推动两国经贸合作提质升级，并带来显著的社会和民 生效益。" 国之交在于民相亲，民相亲在于心相通。"韩中关系的未来根植于两国人民间的友好情谊，需要增加接 触交流，需要增进相互理解，需要 ...

Group 1: Business Strategy and Optimization - The company focuses on high-efficiency business development, actively abandoning low-efficiency operations to invest in high-yield sectors like medical devices and pharmaceuticals [3] - In 2025, the medical device segment generated approximately CNY 4.986 billion in revenue, establishing a stable scale and professional service barrier [4] - The company aims to enhance overall profitability by optimizing its business structure and improving the operational quality of its subsidiaries [3] Group 2: Market Trends and Opportunities - The pharmaceutical distribution industry is experiencing increasing concentration, with resources shifting towards leading enterprises, which creates favorable conditions for market resource integration [5] - The total sales of seven major categories of pharmaceutical products in China is projected to reach CNY 29.47 trillion in 2024, reflecting a year-on-year growth of 0.6% [5] - The company plans to leverage its scale advantages to actively integrate regional resources while focusing on core sectors of medical devices and pharmaceuticals [5] Group 3: Competitive Advantages - The company’s medical device segment benefits from a sales agency model, collaborating with renowned brands like Boston Scientific and Johnson & Johnson, which enhances its competitive edge [4] - Compared to pharmaceutical operations, the medical device business is less affected by centralized procurement, providing stronger risk resistance [5] - The company emphasizes a flexible decision-making mechanism and customer service orientation, allowing for rapid strategic adjustments in response to market changes [7] Group 4: Innovation and Future Planning - The company is actively exploring innovative business models, including the development of innovative drugs, biopharmaceuticals, and high-margin generic drugs [6] - The innovative drug HW130 has completed Phase I clinical trials and is currently in Phase II, with plans to utilize existing retail channel resources for effective product conversion [7] - The company is committed to enhancing its core competitiveness by optimizing product and service offerings in response to market demand changes [8] Group 5: Regulatory and Industry Position - The company ranks ninth among the top 100 pharmaceutical wholesale enterprises in terms of main business revenue, according to the 2024 report by the Ministry of Commerce [8] - The company adheres to legal regulations regarding information disclosure and actively engages with investors to protect their rights [4]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SOUTH CHINA FINANCIAL HOLDINGS LIMITED 南 華 金 融 控 股 有 限 公 司 （於香港註冊成立之有限公司） （股份代號：00619） 董事會謹此強調，截至本公告日期，尚未就建議成立合營公司訂立任何具法律約 束力之協議。因此，建議成立合營公司之事宜未必會落實。本公司股東及潛在投 資者於買賣本公司證券時務請審慎行事。 承董事會命 South China Financial Holdings Limited 南華金融控股有限公司 執行董事 張賽娥 自願公告 有關建議成立合營公司 之諒解備忘錄 本公告由南華金融控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自 願 發 佈 ， 旨 在 通 知 本 公 司 的 股 東 及 潛 在 投 資 者 本 集 團 最 新 的 經 營 策 略 及 發 展 方 向 ...

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 decreased to $1,165,000 from $1,958,000 in the same period a year ago, primarily due to declines in research and development revenue and license and milestone revenue [23][24] - Research and development expenses increased to $572,000 from $460,000 year-over-year, driven by a rise in active internal research initiatives [24] - Net loss for Q3 2025 increased to $1,976,000 or $0.06 per share compared to a loss of $203,000 or $0.01 per share in the same period last year [25] Business Line Data and Key Metrics Changes - The Life Sciences segment is now operating as a product company, manufacturing and supplying lab-grade materials for multiple recombinant proteins [5][6] - The recombinant human albumin program is advancing towards a commercial launch in early 2026, with significant milestone payments received from ProLiant [6][7] - The first bulk purchase order for a Dyadic produced protein was achieved in October, validating the market readiness of the technology [8] Market Data and Key Metrics Changes - The cell culture media market is identified as a dynamic growth area, requiring consistent animal-free proteins for scalability and regulatory confidence [6] - The market for DNase one is approximately $250 million for recombinant products, with a broader market of $1.5 billion for all production methods [32] - The animal-free dairy protein market is expected to exceed $20 billion by 2035, driven by demand for sustainable protein production [13] Company Strategy and Development Direction - The company is transitioning from a platform-centric R&D organization to a commercially focused biotechnology company with a growing portfolio of high-value products [4][5] - Dyadic has rebranded as Dyadic Applied Biosolutions and is enhancing its technology foundation with CRISPR Cas9 gene editing capabilities [4][5] - The strategy includes expanding customer engagement in key global markets, particularly in Asia, Europe, and North America [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's transformation and execution, highlighting the first commercial bulk sale as a pivotal moment [4][5] - The focus remains on accelerating product sales across life sciences and molecular biology reagent portfolios, with early commercial traction already underway [76] - The company anticipates growth in product revenue in life sciences and food and nutrition markets while maintaining operating expenses in line with the previous year [26] Other Important Information - The company received a total of $1,500,000 in milestone payments from ProLiant, with expectations to share in profits as albumin products enter the market [7] - Dyadic's collaboration with Intralink aims to accelerate market penetration in Japan and South Korea, leveraging local expertise for effective market reach [11][12] Q&A Session Summary Question: What does the new relationship with ERS Genomics bring to the portfolio? - The CRISPR license enhances the genetic toolbox, accelerating product development and improving optimization yields, providing a competitive advantage in various markets [29][30] Question: How should the DNase one opportunity be viewed for growth in 2026 and beyond? - The DNase one market is substantial, and the focus is on securing OEM agreements for bulk sales, with expectations for steady growth as higher margin segments are targeted [32][34] Question: What characteristics of customers are expected in the Asian markets for DNase one and transferrin? - The target customers include cell and gene therapy manufacturers and suppliers, focusing on bulk purchase orders rather than individual institutions [36][37] Question: Can you elaborate on the CRISPR ERS agreement structure? - The agreement involves improving fungal cell lines for efficiency and quality, with confidentiality around financial specifics, but it is not comparable to CRISPR applications in pharmaceuticals [45][46] Question: How is the infant nutrition product being marketed? - The goal is to mimic human breast milk and bovine milk, with a focus on regulatory hurdles and consumer acceptance, presenting a significant opportunity in the market [51][53]

Core Viewpoint - Waters Corporation reported a strong Q3 performance with sales of $800 million, an 8% year-over-year increase, exceeding market expectations for both revenue and profit [3][10]. Group 1: Pharmaceutical Market Performance - The pharmaceutical segment experienced a robust demand, achieving an 11% year-over-year growth, with double-digit increases in both the Americas and Asia, while Europe maintained a solid single-digit growth [3][10]. - The Chinese market was a key highlight, with pharmaceutical sales growing over 20% year-over-year, reflecting increased R&D investments from local CDMO and biotech companies [3][10]. - Revenue related to GLP-1 testing doubled globally, driven by the expansion of drug development and production in the Americas and Europe [3][10]. Group 2: Instrument Sales and Innovations - Instrument sales grew by 11% quarter-over-quarter, marking the best performance outside of the pandemic year of 2020, supported by a comprehensive product matrix [7][8]. - The Alliance series HPLC products saw over 300% year-over-year growth, indicating strong user recognition of the platform [8]. - The Xevo™ TQ Absolute series platform grew by 30% year-over-year, bolstered by the market introduction of the new Xevo™ TQ Absolute XR model [8][10]. Group 3: Technological Advancements - Waters is enhancing its core technological advantages in large molecule drug analysis, launching the Xevo™ charge detection mass spectrometer, which offers ten times faster analysis speed and requires only 1% of the sample volume compared to traditional methods [12][18]. - The Empower platform is being upgraded to integrate various technologies, including flow cytometry, to create a unified, compliant data environment, with cloud and AI/ML functionalities expected by 2026 [14][18]. Group 4: Strategic Integration and Long-term Growth - Waters is actively pursuing a merger with BD Biosciences and Diagnostic Solutions, expected to complete in Q1 2026, which will enhance its product portfolio and market access, particularly in high-growth areas like cancer immunotherapy and personalized medicine [17][18]. - The company aims to leverage the merger to accelerate its long-term growth strategy while maintaining high standards of innovation and operational execution [17][18].

Financial Data and Key Metrics Changes - Total revenue increased by 11% in the first nine months of 2025, driven by strong demand for innovative medicines [6][11] - Core EPS rose by 15%, reflecting robust underlying business momentum [14] - Alliance revenue surged by 41%, primarily due to growth from Enhertu and Tezspire [11] - Core gross margin was reported at 83%, with expectations of a slight decrease for the full year due to various factors [12][15] Business Line Data and Key Metrics Changes - Oncology franchise revenue grew by 16%, with Tagrisso achieving $1.9 billion in sales, marking a 10% increase year-on-year [17][19] - Biopharmaceuticals revenue reached $17.1 billion, reflecting an 8% growth, with significant contributions from Fasenra and Tezspire [31] - Rare disease medicines grew by 6% to $6.8 billion, driven by strong demand for Ultomiris and Koselugo [40] Market Data and Key Metrics Changes - U.S. revenues increased by 19%, while emerging markets outside of China saw a 21% growth [7] - The U.S. is projected to account for around 50% of total revenue by 2030 [9] - China’s revenue growth is anticipated to be affected by stock compensation costs and year-end hospital budget capping [16] Company Strategy and Development Direction - The company aims to achieve $80 billion in revenue by 2030, supported by a rich pipeline of upcoming product launches and regulatory approvals [8][45] - A landmark agreement with the U.S. government aims to provide clarity around pricing and safeguard biopharmaceutical innovation [9] - Continued investment in R&D is planned, with a focus on high-value pipeline opportunities and expanding global manufacturing capacity [15][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company’s ability to navigate regulatory changes and maintain growth momentum [49] - The company anticipates strong revenue momentum in growth brands to continue, despite potential headwinds from product exclusivity losses [15][52] - Positive results from multiple pivotal studies are expected to reshape clinical practice and drive future growth [23][29] Other Important Information - The company is expanding its manufacturing footprint in the U.S. and has broken ground on a new facility in Virginia [10] - AstraZeneca ordinary shares will be listed on the New York Stock Exchange from February next year, enhancing capital access [10] Q&A Session Summary Question: What is the risk of residual activity from the administration regarding pricing? - Management addressed concerns by stating that the agreement with the U.S. government covers key points and they do not expect further issues [49] Question: Is the $10 billion catalyst potential part of the $80 billion ambition? - The $10 billion is part of the $80 billion peak-year revenue potential, contributing to the overall 2030 goal [50] Question: What is the comfort level regarding 2026 margin consensus? - Management indicated that while there are pushes and pulls, they remain committed to investing in growth brands and maintaining strong margins [51][52]

Key Insights - The report highlights a significant improvement in industry profitability, with a focus on sectors such as non-bank financials, transportation, electronics, coal, and power equipment showing notable quarterly net profit growth [8][21]. - The automotive seating business of the company has turned profitable for the first time in Q3 2025, driven by increased orders from key models [12][15]. - The company has adjusted its profit forecasts for 2025-2027, expecting net profits of 4.12 billion, 8.10 billion, and 11.54 billion respectively, reflecting a positive outlook on new project production schedules [15][20]. Group 1: Industry Overview - The global asset review indicates mixed performance in stock markets, with the Nikkei 225 leading gains, while commodity prices showed volatility, particularly in oil and gold [6]. - The manufacturing PMI for October 2025 was reported at 49.0%, indicating a contraction influenced by trade tensions, while the non-manufacturing PMI slightly improved to 50.1% [21][24]. - The report notes that the construction industry is expected to see a rise in activity due to government investment initiatives, with a significant increase in the business activity expectation index [21][24]. Group 2: Company-Specific Insights - The company reported a Q3 2025 revenue of 56.00 billion, with a net profit of 0.97 billion, marking a 97% increase quarter-on-quarter [11][12]. - The integration of the subsidiary, Gramer, has shown significant operational improvements, particularly in the European market, despite a decline in revenue [14]. - The company is focusing on cost reduction and efficiency improvements to counteract industry pressures, maintaining its leading position in the global headrest market [13][15]. Group 3: Financial Performance - The company’s Q3 2025 results showed a significant recovery in profitability, with a gross margin of 15.72%, reflecting a year-on-year increase [12]. - The report indicates that the company’s cash flow has been impacted by cyclical challenges, with a notable decline in operating cash flow [32]. - The company’s net profit for Q3 2025 was significantly boosted by the reduction in raw material costs and improved operational efficiencies [31][32].

Core Points - The article highlights the significance of bilateral meetings between Chinese President Xi Jinping and leaders from five countries during the APEC summit, marking their first face-to-face interactions [1][3][5][7][9][11] - The meetings are seen as a strategic move to strengthen bilateral relations and cooperation in various sectors, including traditional and emerging industries [7][9][11] Group 1: Bilateral Meetings - Xi Jinping's meeting with U.S. President Trump is noted as their first meeting during Trump's presidency, emphasizing the importance of establishing a stable foundation for U.S.-China relations [3] - During the meeting with Canadian Prime Minister Carney, Xi expressed a desire to restore healthy and stable relations between China and Canada [5] - In discussions with Japanese Prime Minister Suga, Xi highlighted the coexistence of opportunities and challenges in China-Japan relations, urging for a correct understanding of China [7] Group 2: Cooperation Areas - The bilateral discussions covered a wide range of cooperation areas, including high-end manufacturing, finance, agriculture, artificial intelligence, biopharmaceuticals, green industries, and the silver economy [7][9] - Leaders from South Korea and Thailand expressed their willingness to enhance cooperation with China in various fields, including trade, technology, and tourism [9][11] Group 3: Cultural and People-to-People Exchanges - Xi emphasized the importance of cultural exchanges and public sentiment in strengthening bilateral ties, advocating for increased people-to-people interactions [11] - The article suggests that fostering mutual understanding and enhancing grassroots connections are essential for the long-term stability of major power relations [11]